Medicine guide

Infant Dextrose

250 mg/mL · Injection, Solution

Prescription only

Active substance: Dextrose
Made by: Henry Schein, Inc.
Source: Official label

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

At a glance

Quoted from the official label · 2026-07-13

The FDA lists a current shortage of dextrose

Not necessarily this product — shortages are reported per presentation. Your pharmacy will know. · Updated 2026-09-22 FDA drug shortages

Used for

Dextrose Injection (25%) is indicated for the treatment of acute symptomatic episodes of hypoglycemia in pediatric patients from birth up to 2 years of age.

The label’s usual adult dose

The recommended initial dose is 250 mg/kg to 500 mg/kg (1 mL/kg to 2 mL/kg). If clinically indicated, additional single doses of 250 mg/kg to 500 mg/kg (1 mL/kg to 2 mL/kg) may be administered. (2.2)

Full directions ↓

Do not take it if

Dextrose Injection (25%) is contraindicated in patients with:

All warnings ↓

Good to know

Prescription only
FDA enforcement reports list no ongoing recall, and none from the last two years, for this product code · checked 2026-10-02

10other products contain Dextrose — compare makers, forms and strengths

Every line above is selected, not written, from the official label. Nothing is reworded. DailyMed

What it is for

Dextrose Injection (25%) is indicated for the treatment of acute symptomatic episodes of hypoglycemia in pediatric patients from birth up to 2 years of age.
Dextrose Injection (25%) is indicated for the treatment of acute symptomatic episodes of hypoglycemia in pediatric patients younger than 2 years old.
(1)

From the official label · 2026-07-13 · DailyMed

How it works

From this product’s own US prescribing label.

Pharmacology 12.1 Mechanism of Action Dextrose restores blood glucose levels and provides a source of carbohydrate calories. 12.2 Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of dextrose have not been fully characterized. 12.3 Pharmacokinetics Dextrose is oxidized to carbon dioxide and water.

Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-07-13

Do not take it if

Dextrose Injection (25%) is contraindicated in patients with:
Intracranial or intraspinal hemorrhage because Dextrose Injection (25%) can worsen cerebral edema by causing a fluid shift across the blood-brain barrier.
Severe dehydration because of the potential to worsen the patient’s hyperosmolar state.
Known hypersensitivity to dextrose [see Warnings and Precautions (5.2)].
Intracranial or intraspinal hemorrhage. (4)
Severe dehydration. (4)
Hypersensitivity to dextrose. (4)

Quoted from the official label, section “Contraindications”.

How to take it

These directions are for this exact strength and form. Another one is different.

Important Preparation and Administration Instructions
Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration.
Do not use Dextrose Injection (25%) if the solution is cloudy or the seal has been broken.
Obtain blood glucose level prior to administering Dextrose Injection (25%). However, in cases of emergency, administer Dextrose Injection (25%) promptly without awaiting blood glucose test results.
Administer Dextrose Injection (25%) via slow intravenous injection into a central vein to reduce the risk of developing hyperglycemia and to minimize venous irritation [see Warnings and Precautions (5.1, 5.3)].
Do not administer Dextrose Injection (25%) simultaneously with blood through the same infusion set because pseudoagglutination of red blood cells may occur.
Administer Dextrose Injection (25%) intravenously. Do not administer Dextrose Injection (25%) subcutaneously or intramuscularly.
Discard the unused portion.
Only for intravenous infusion. Do not administer subcutaneously or intramuscularly. (2.1)
The recommended initial dose is 250 mg/kg to 500 mg/kg (1 mL/kg to 2 mL/kg). If clinically indicated, additional single doses of 250 mg/kg to 500 mg/kg (1 mL/kg to 2 mL/kg) may be administered. (2.2)
Infusion rate depends on the age, weight, and clinical and metabolic conditions of the patient and concomitant therapy. (2.2)
See full prescribing information for more information on preparation, administration instructions, and dosing considerations. (2.1, 2.2)

Quoted from the official label, section “Dosage & Administration”.

Other warnings

5.1 Hyperglycemia and Hyperosmolar Hyperglycemic State Significant hyperglycemia and hyperosmolar hyperglycemic state may result from too rapid administration of Dextrose Injection (25%). Symptoms of hyperosmolar hyperglycemic state include mental confusion and loss of consciousness. To minimize these risks, slowly inject Dextrose Injection (25%) and monitor blood glucose levels before and after treatment with Dextrose Injection (25%). Due to the increased risk of hyperglycemia in neonates and low birth weight infants, use caution when selecting the dosage and injection rate of Dextrose Injection (25%). 5.2 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, have been reported with Dextrose Injection (25%) administration [see Adverse Reactions (6)]. Stop administration of Dextrose Injection (25%) immediately if signs or symptoms of a hypersensitivity reaction develop. Initiate appropriate treatment as clinically indicated. 5.3 Phlebitis and Thrombosis Dextrose Injection (25%) is hypertonic (has an osmolarity greater than 900 mOsm/L) and may cause phlebitis and thrombosis at the site of injection. If thrombophlebitis occurs, remove the catheter as soon as possible. Administer Dextrose Injection (25%) via slow intravenous injection into a central vein to reduce the risk of phlebitis and thrombosis. Ensure that the needle is well within the lumen of the vein and that extravasation does not occur. If thrombosis occurs, stop administration of Dextrose Injection (25%) and initiate corrective measures. If central venous access cannot be obtained in these pediatric patients, consider using an alternative commercially available dextrose product with a lower concentration. Do not administer Dextrose Injection (25%) subcutaneously or intramuscularly. 5.4 Electrolyte Imbalance and Fluid Overload Electrolyte deficits, particularly serum potassium and phosphate, may occur during prolonged use of Dextrose Injection (25%). Depending on the administered volume and the infusion rate, administration of Dextrose Injection (25%) can cause fluid overload, including pulmonary edema.
Avoid Dextrose Injection (25%) in patients at risk for fluid and/or solute overload. If use cannot be avoided in these patients, monitor fluid balance, electrolyte concentrations, and acid base balance, especially during prolonged use. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration, and/or free water load. 5.5 Hyponatremia Dextrose Injection (25%) may cause hyponatremia. Hyponatremia can lead to acute hyponatremic encephalopathy characterized by headache, nausea, seizures, lethargy, and vomiting. The risk of hospital-acquired hyponatremia is increased in younger pediatric patients, and patients treated with diuretics, and patients with cardiac or pulmonary failure or with the syndrome of inappropriate antidiuretic hormone (SIADH) (e.g., postoperative patients, patients concomitantly treated with arginine vasopressin analogs or certain antiepileptic, psychotropic, and cytotoxic drugs) [see Drug Interactions (7.1) and Use in Specific Populations (8.4)].
Avoid Dextrose Injection (25%) in patients with or at risk for hyponatremia. If use cannot be avoided, closely monitor serum sodium concentrations, chloride concentrations, fluid status, acid-base balance, and neurologic status [see Warnings and Precautions (5.4)]. 5.6 Neonatal Adverse Reactions from Unapproved Maternal Use at Time of Delivery Dextrose Injection (25%) is not approved for use in adolescents or
adults. Maternal hyperglycemia secondary to the use of concentrated dextrose solutions at the time of delivery has been associated with adverse outcomes such as neonatal hypoglycemia.
Hyperglycemia or Hyperosmolar Hyperglycemic State :
Monitor blood glucose levels before and after treatment. Use caution when selecting the dosage and injection rate due to the increased risk of hyperglycemia in neonates and low birth weight infants. (5.1)
Hypersensitivity Reactions :
Monitor for signs and symptoms and discontinue infusion immediately if reaction occurs. (5.2)
Phlebitis and Thrombosis :
Remove catheter as soon as possible if thrombophlebitis develops. (2.1, 5.3)
Monitor changes in fluid balance, electrolyte concentrations, and acid-base balance during administration. (5.4)
Hyponatremia :
Monitor serum sodium and chloride concentrations, fluid status, acid-base balance, and neurologic status. (5.5)
Neonatal Adverse Reactions from Unapproved Maternal Use at Time of Delivery :
Maternal hyperglycemia at the time of delivery has been associated with adverse outcomes such as neonatal hypoglycemia.

Quoted from the official label, section “Warnings”.

Pregnancy and breastfeeding

In Specific Populations
8.4 Pediatric Use Dextrose Injection (25%) is indicated for the treatment of acute symptomatic episodes of hypoglycemia in pediatric patients from birth up to 2 years of age.
Dextrose Injection (25%) can increase the risk of developing hypo- or hyperglycemia in neonates, especially preterm neonates with low birth weight.
Excessive or rapid administration of Dextrose Injection (25%) may also result in increased serum osmolality and increase the risk of intracerebral hemorrhage in very low birth weight neonates [see Warnings and Precautions (5.1)].
Monitor plasma electrolyte concentrations closely in pediatric patients who may have impaired ability to regulate fluids and electrolytes.
Pediatric patients treated with Dextrose Injection (25%) are at increased risk of developing hyponatremia and hyponatremic encephalopathy [see Warnings and Precautions (5.4, 5.5)].
Dextrose Injection (25%) is not indicated in pediatric patients 2 years of age and older.

Quoted from the official label, section “OTC — Pregnancy or Breast Feeding”.

Other medicines

7.1 Drugs with Effects on Glycemic Control and Electrolyte Balance Dextrose Injection (25%) can affect glycemic control, vasopressin, and fluid and/or electrolyte balance [see Warnings andPrecautions (5.1, 5.4, 5.5)].
Monitor patients’ blood glucose concentrations, fluid balance, serum electrolyte concentrations, and acid-base balance.
Concomitant administration of Dextrose Injection (25%) with drugs associated with hyponatremia may increase the risk of developing hyponatremia.
Drugs associated with hyponatremia include diuretics and those that cause SIADH (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), arginine vasopressin analogs, certain antiepileptic, psychotropic, and cytotoxic drugs).
Avoid use of Dextrose Injection (25%) in patients receiving drugs associated with hyponatremia.
If use cannot be avoided, closely monitor serum sodium concentrations during concomitant use [see Warnings and Precautions (5.5)].

Quoted from the official label, section “Drug Interactions”.

If you take too much

In an emergency, call your local emergency number or a poison control centre.

A medication error resulting in a high infusion rate of Dextrose Injection (25%) can cause hyperglycemia, hyperosmolality, and adverse effects on fluid and electrolyte balance [see Warnings and Precautions (5.1, 5.4)].
Severe hyperglycemia and severe dilutional hyponatremia, and their complications, can be fatal.
In the event of overdosage (overhydration or solute overload) during Dextrose Injection (25%) treatment, discontinue the infusion.
Institute corrective measures such as administration of exogenous insulin, and treat adverse effects on the CNS, respiratory, and cardiovascular systems [see Warnings and Precautions (5.1, 5.4)].

Quoted from the official label, section “Overdosage”.

Side effects

The following clinically significant adverse reactions are also described elsewhere in the labeling:
Hyperglycemia and Hyperosmolar Hyperglycemic State [see Warnings and Precautions (5.1)].
Hypersensitivity Reactions [see Warnings and Precautions (5.2)].
Phlebitis and Thrombosis [see Warnings and Precautions (5.3)]
Electrolyte Imbalance and Fluid Overload [see Warnings and Precautions (5.4)]
Hyponatremia [see Warnings and Precautions (5.5)] The following adverse reactions associated with the use of Dextrose Injection were identified in clinical trials or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Administration site conditions:
blister, extravasation, phlebitis, erythema, pain, vein damage, thrombosis
Immune system disorders:
anaphylaxis, angioedema, bronchospasm, chills, hypotension, pruritis, pyrexia, rash
Cardiovascular disorders:
cyanosis, volume overload The most common adverse reactions are hyperglycemia, hypersensitivity reactions, hyponatremia, infection (both systemic and at the injection site), vein thrombosis, phlebitis, and electrolyte imbalance. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Revised 7/2025

Quoted from the official label, section “Adverse Reactions”.

Strengths and forms

Forms and Strengths Injection:
25% (2.5 g/10 mL) (250 mg/mL) of dextrose hydrous, in a clear, colorless solution in a single-dose Ansyr™ Plastic Syringe Injection:
25% (2.5 g/10 mL) (250 mg/mL) of dextrose hydrous in a clear, colorless solution in a single-dose Ansyr™ Plastic Syringe. (3)

Quoted from the official label, section “Dosage Forms & Strengths”.

What it looks like and how it is packed

How Supplied Dextrose Injection, USP (25%) is supplied as a clear, colorless solution in single-dose syringe as follows:
Storage and Handling
Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature.] Product repackaged by:
Henry Schein, Inc., Bastian, VA 24314 From Original Manufacturer/Distributor's NDC and Unit of Sale To Henry Schein Repackaged Product NDC and Unit of Sale Total Strength/Total Volume (Concentration) per unit NDC 0409-1775-10 Bundle of 10 Ansyr™ Plastic Syringes Single-dose containers NDC 0404-9844-10 1 10 mL Single-dose syringe in a bag (Syringe bears NDC 0409-1775-40) 2.5 g/10 mL (250 mg/mL) To contact Pfizer's Medical Information Department, please visit www.pfizermedinfo.com or call 1-800-438-1985.
Distributed by Hospira, Inc., Lake Forest, IL 60045 USA Image1.jpg

Quoted from the official label, section “How Supplied”.

What is in it

Dextrose, USP is chemically designated D-glucose monohydrate, (C 6 H 12 O 6
H 2 O), a hexose sugar freely soluble in water, with the following structural formula:
Water for Injection, USP is chemically designated H 2 O. The molecular weight of dextrose (D-glucose) monohydrate is 198.17. Dextrose Injection, USP (25%) is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection. Each milliliter (mL) of fluid contains 0.25 grams of dextrose, hydrous, which delivers 3.4 kcal/gram (0.85 kcal/mL). The solution has an osmolarity of 1.39 mOsmol/mL (calculation) and the pH range is 3.2 to 6.5. May contain hydrochloric acid and sodium hydroxide for pH adjustment. The solution contains no bacteriostatic, antimicrobial agent or added buffer (except for pH adjustment) and is supplied in a single-dose Ansyr™ Plastic Syringe. Dextrose is derived from corn. Formula1.jpg

Quoted from the official label, section “Description”.

Ingredients people check for

Lactose, gluten, dyes, sugars and other ingredients that matter with an allergy, intolerance or diet — as this product’s FDA label lists them.

The stored label for this product has no list of inactive ingredients. The list on the pack is the one to check.

Quoted from the FDA label. A label that does not name an ingredient is not a guarantee that the product is free of it, and formulations change. With an allergy, check the pack and ask a pharmacist.

Every version of this medicine (4)

The same active substance, strength and kind of form, from every company that sells it — with what each label lists.

Showing 4 of 4

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

CanadaNo exact match for this strength and form

Every strength and form (14)

Details

Made by	Henry Schein, Inc.
Active substance	Dextrose
Strength	250 mg/mL
Form	Injection, Solution
Route	Intravenous
Packs	1 SYRINGE in 1 BAG / 10 mL in 1 SYRINGE
NDC	0404-9844

Source: NDC Directory · 2026-09-13 · not reviewed by a clinician

Source: US Food and Drug Administration, NDC Directory. Reuse terms: US government work (FDA).

Report wrong or outdated information on this page

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.

Dextrose50 mg/mLPrescription onlyInjection, Solution B. Braun Medical Inc. · Dextrose Dextrose70 g/100mLPrescription onlySolution B. Braun Medical Inc. · Dextrose Dextrose5 g/100mLPrescription onlySolution B. Braun Medical Inc. · Dextrose Dextrose10 g/100mLPrescription onlySolution B. Braun Medical Inc. · Dextrose Dextrose20 g/100mLPrescription onlyInjection, Solution ICU Medical Inc. · Dextrose Dextrose50 g/100mLPrescription onlyInjection, Solution ICU Medical Inc. · Dextrose

See every product with Dextrose